Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating income | -$41.3M | -$52.7M | -$12.0M | -$37.0M | -$49.0M | -$91.7M | -$119M | -$99.2M | -$98.1M | -$103M |
| Net income | -$41.0M | -$52.1M | -$11.5M | -$34.9M | -$44.0M | -$92.9M | -$120M | -$93.6M | -$101M | -$97.2M |
| EPS (diluted) | -$1.31 | -$1.31 | -$13.63 | -$4.52 | -$2.81 | -$3.93 | -$3.78 | -$2.11 | -$1.00 | -$0.62 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$35.8M | -$40.4M | -$9.74M | -$28.5M | -$46.1M | -$83.2M | -$65.1M | -$70.8M | -$84.8M | -$85.8M |
| Capital expenditures | $556K | $685K | $32.0K | $55.0K | $146K | $67.0K | $112K | $334K | $264K | $161K |
| Free cash flow | -$36.3M | -$41.1M | -$9.77M | -$28.6M | -$46.3M | -$83.3M | -$65.3M | -$71.2M | -$85.0M | -$86.0M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $60.0M | $56.9M | $13.1M | $29.4M | $127M | $86.9M | $107M | $46.7M | $35.7M | $15.5M |
| Total assets | $64.0M | $60.4M | $13.4M | $66.0M | $168M | $139M | $128M | $54.3M | $40.9M | $24.1M |
| Total liabilities | — | — | $1.92M | $7.59M | $9.08M | $12.0M | $14.1M | $25.4M | $22.4M | $30.7M |
| Shareholders' equity | $58.4M | -$13.3M | -$25.7M | $58.4M | $159M | $127M | $114M | $28.9M | $18.4M | -$6.67M |
| Retained earnings | -$244M | -$296M | -$25.0M | -$59.9M | -$104M | -$197M | -$317M | -$411M | -$511M | -$609M |
| Shares (wtd avg diluted) | 32.1M | 42.4M | 847K | 10.7M | 15.7M | 23.7M | 31.8M | 44.3M | 100M | 156M |
Every figure is extracted from IMMUNIC, INC.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.